Katharina Gasser – Managing Director, Biogen Switzerland…
Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why…
Tagged with Biogen
Market Access in Switzerland: Reimbursement Delays for 76% of New…
Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to…
Aducanumab: On the Regulatory Home Stretch in the USA
In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr…
Ivan Cheung – Chairman, Eisai Inc.; President, Neurology…
Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease…
Luis Calderon – General Manager, Biogen Mexico
Biogen Mexico’s Luis Calderon discusses establishing the affiliate, the opportunities apparent in the Mexican neurodegenerative disease market, and…
Worried About Biogen’s Aducanumab? Don’t Be
Dr Neil Cashman examines the recent news around Biogen’s Alzheimer’s treatment aducanumab, assuages some investor fears, and underlines…
Alzheimer’s Disease Treatment: Canadian-Led Innovation…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD)…
Biogen Canada’s Marina Vasiliou: A 100% Commitment to…
Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied career at MSD in a wide variety of…
Martin Dubuc – General Manager, Biogen France
Martin Dubuc, general manager of Biogen France, discusses the company’s strong leadership in neurosciences, its commitment to pioneering the…
Biogen: The Only Hope for Alzheimer’s?
After completing Phase II of clinical trials, Biogen and Eisai’s new candidate drug for Alzheimer’s Disease is showing strong potential in a field…
Brexit: A Serious Threat to Patients
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit…
Interview: Terry O'Regan – Vice President and Managing…
Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues,…
